[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RDC Clinical Pty Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":211},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,68,91,117,140,167,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644094","phase-4-vitamin-b12-absorption-study-100644094",false,"NCT07665671","Vitamin B12 Absorption Study","A Randomized, Double-Blind, Cross-Over Clinical Trial to Compare the Absorption of Different Forms of Vitamin B12 (AMPLIB12)","Inclusion Criteria:\n\n1. Males and females 50 years of age and older\n2. BMI between 18 to 29.9 kg\u002Fm2\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Woman of child-bearing potential (WOCBP) must be following appropriate contraceptive methods until the last visit:\n   * Sexual abstinence.\n   * Oral contraceptive.\n   * Trans dermal patches or depot injection of a progestogen drug (starting at least 4 weeks prior to product administration).\n   * Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration).\n   * Sterilised male partner (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).\n   * Contraceptives must be effective before product administration.\n4. Agrees not to take any vitamin B12 containing supplements until the completion of the study.\n5. Agrees to avoid consuming liver, kidney, organ meats and very high B12 containing shellfish (e.g. clams and crab) 72 hours prior to study visits\n6. Agrees to consume the standardized meals for each of the study visits\n7. Agrees to avoid alcohol intake 48 hours prior to study visits\n8. Agrees to maintain current lifestyle habits (physical activity, medications, supplements, and sleep) as much as possible throughout the study\n9. Able to fast for 10 hours prior to study visits\n10. Provided voluntary, written, informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational products\n3. History or current diagnosis of any clinically significant disease that may alter vitamin B12 absorption, accumulation, metabolism or excretion\n4. Taking vitamin B12 supplements or a multivitamin supplement containing vitamin B12 within the prior 2 months from study product administration.\n5. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the absorption of vitamin B12\n6. Have a serious illness e.g. mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, diabetes, liver disease, autoimmune disease, bleeding disorders or heart conditions\n7. Have an unstable illness e.g. diabetes and thyroid gland dysfunction\n8. Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years\n9. Gastrointestinal or absorption issues (IBD, IBS, Celiac disease, Crohn's disease, history of GI surgery, Small Intestinal Bacterial Overgrowth)\n10. Poor venous access\n11. Current use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n12. Active smokers, nicotine use or drug (prescription or illegal substances) abuse.\n13. Chronic past and\u002For current alcohol use (\\>14 alcoholic drinks week)\n14. Blood donation 60 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n15. Participation in other clinical research studies 30 days prior to baseline, as assessed by the PI\n16. Any other condition or lifestyle factor, that, in the opinion of the PI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",true,"ALL","50 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This randomized, double-blind, crossover trial (Phase IV) aims to compare the absorption of a novel permeability-enhanced oral vitamin B12 formulation (Ampli-B) versus standard oral vitamin B12 in 12 healthy adults aged 50 years and older. Each participant receives a single dose of each formulation in randomized sequence, separated by a minimum 10-day washout. The primary outcome is time to peak serum concentration (Tmax) of total and active vitamin B12 (holotranscobalamin). Secondary outcomes include Cmax and AUC parameters.",[27],"Healthy Volunteers",[29],"50 years and older","NOT_YET_RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":21},"2026-07",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"RDC Clinical Pty Ltd","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100642225","phase-2-a-novel-cold-and-flu-herbal-blend-for-reducing-the-duration-and-severity-of-the-common-cold-100642225","NCT07642648","A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold","A Randomized Blinded Controlled Trial Evaluating the Efficacy of a Novel Herbal Cold and Flu Blend in Reducing the Duration and Severity of Symptoms of the Common Cold","NOURTI","Inclusion Criteria:\n\n* Adults aged 18-65 years living in Australia\n* Individuals with a history of recurrent Upper Respiratory Tract infections (URTI) (at least one episode per year)\n* Able to provide informed consent\n* Generally healthy\n* Agree to not participate in another clinical trial while enrolled in this trial\n* Agree to maintain their usual daily activities without significant changes. This includes not changing their current diet or stopping\u002Fstarting a new exercise regimen during entire study period\n* Females of childbearing potential must use a prescribed form of birth control (e.g. oral contraceptive)\n\nExclusion Criteria:\n\n* Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, autoimmune conditions, neurological disorders such as multiple sclerosis.\n* Unstable illness e.g., changing medication\u002Ftreatment.\n* BMI \\\u003C18.5, \\>30\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.\n* Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease).\n* Active smokers, nicotine use (including vaping\u002Fe-cigarettes) or drug (prescription or illegal substances) abuse\n* Current alcohol use (\\>21 alcoholic drinks week)\n* Allergic to any of the ingredients in the active or placebo formula\n* Allergic to plants in the Asteraceae family\n* Pregnant or lactating woman\n* Regular use of medications that would affect the immune and\u002For the inflammatory response e.g. antihistamines, anti-inflammatories, immunosuppressants, steroids excluding topical steroid use.\n* Use of anticoagulant medications such as warfarin.\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month\n* Participants with allergic rhinitis\n* Regular use of antihistamines\n* Individuals deemed unsuitable for participation by the Principal Investigator (PI) of this study.","18 Years","65 Years",{"count":54,"type":21},300,[56],"PHASE2","The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \\& Flu Blend in reducing the duration of symptoms of the common cold. The secondary objective is to assess whether the investigational product reduces the severity of symptoms. Participants will be enrolled for 16 weeks, during this period they will take the assigned study product when they experience URTI symptoms.",[59,60],"URTI","Common Cold","2026-06-07",{"date":63,"type":34},"2026-06-11",{"date":36,"type":21},{"date":66,"type":21},"2027-12",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100628137","phase-2-gut-microbiome-and-metabolic-health-study-100628137","NCT07457723","Gut Microbiome and Metabolic Health Study","A Double-blind, Randomised, Placebo-controlled Parallel Study to Assess the Effectiveness of TRPTI (Oleoylethanolamide) Compared to Placebo on Gut Microbiome and Plasma Biomarker Changes in Healthy Adults","IMPTRP","Inclusion Criteria:\n\n* Adults aged 18 years and above\n* Generally healthy\n* BMI 18.5-29.9 kg\u002Fm2\n* Able to provide informed consent\n* Agree to not participate in another clinical trial while enrolled in this trial\n* Agree not to change current diet and\u002For exercise frequency or intensity during entire study period\n* Stable diet and lifestyle for at least 4 weeks prior\n* Females using a prescribed form of birth control (e.g. oral contraceptive)\n\nExclusion Criteria:\n\n* Unstable or serious illness (e.g. Serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, thyroid gland dysfunction)\n* Known gastrointestinal disorders (IBD, IBS, celiac disease, etc.)\n* Use of antibiotics within 8 weeks prior to study entry\n* Regular use of medications that significantly affect gut microbiome (PPIs, laxatives, antacids)\n* Use of probiotics, prebiotics, or symbiotic within 4 weeks prior to study entry\n* Current malignancy (excluding BCC) or chemotherapy and radiotherapy treatment for malignancy within the previous 2 years\n* Active smokers, nicotine use, alcohol or drug (prescription or illegal substances) abuse\n* Chronic past and\u002For current alcohol use (\\>14 alcoholic drinks week)\n* Allergic to any of the ingredients in the active or placebo formula\n* Consistently (3 or more days per week) taken OEA within 4 weeksb prior to study entry\n* Known pregnant or lactating woman\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion\n* Participants who have participated in any other non-RDC related clinical study during the past 1 month\n* History of infection in the month prior to the study",{"count":77,"type":21},90,[56],"The goal of this clinical trial is to assess whether TRPTI (oleoylethanolamide) can reduce plasma imidazole propionate levels and improve insulin sensitivity and metabolic health in healthy adults aged 18 years and above with BMI 18.5-29.9 kg\u002Fm². The main question it aims to answer is does TRPTI reduce plasma imidazole propionate (a gut microbiota-derived metabolite linked to insulin resistance)?\n\nResearchers will compare TRPTI 300 mg to placebo in a parallel design to see if TRPTI reduces imidazole propionate levels and improves metabolic health markers compared to placebo.\n\nParticipants will:\n\n* Take 2 capsules of their assigned study product daily for 8 consecutive weeks\n* Attend 3 clinic visits (at baseline, week 4 and week 8)",[27],[82],"Gut microbiome","2026-05-07",{"date":85,"type":34},"2026-05-12",{"date":87,"type":21},"2026-05",{"date":89,"type":21},"2027-03",{"name":40,"class":41},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":106,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100617199","phase-2-sleep-and-stress-study-100617199","NCT07315516","Sleep and Stress Study","The Effects of Natural Bioactive Compounds on Sleep and Stress: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Generally healthy adults aged 18 and over.\n* Able to provide informed consent.\n* Score of at least 14 on the Perceived Stress Scale (PSS).\n* Those with a sleep complaint with a frequency of at least 2 times per week(1)\n* Agree not to use other dietary supplements for sleep, depression, stress or anxiety other than the investigational product during entire study period.\n* Agree not to change current diet and\u002For exercise frequency or intensity during entire study period.\n* Agree to not participate in another clinical trial during the study period.\n\n  1. Sleep complaints are defined as difficulty initiating sleep, or difficulty maintaining sleep, or early-morning awakening with inability to return to sleep and causing distress or impairment in social, occupational, educational, academic, behavioural, or other important areas of functioning.)\n\nExclusion Criteria:\n\n* A WHO-5 Well-Being Index score ≤ 28\n* Those with severe sleep complaints (Insomnia Severity Index \\>21)\n* Taking prescribed sleep, depression or anxiety medication\n* Have a serious illness e.g. asthma, depression, anxiety disorder, bipolar disorder, insomnia, organic sleep disorders (i.e. sleep apnoea), neurological disorders such as MS, kidney disease, liver disease or heart conditions\n* Have an unstable illness e.g. diabetes and thyroid gland dysfunction\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years\n* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin\n* Active smokers, nicotine use or drug (prescription or illegal substances) abuse\n* Chronic past and\u002For current alcohol use (\\>21 alcoholic drinks week)\n* Those consuming more than 500mg caffeine per day\n* Pregnant or lactating women\n* Allergic to any of the ingredients in active or placebo formula\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion",{"count":99,"type":21},240,[56],"The goal of this clinical trial is to learn if natural supplements (lavender oil, PEA, and OEA) work to improve sleep and reduce stress in adults with moderate stress levels and sleep difficulties. It will also learn about the safety of these natural supplements.\n\nThe main questions it aims to answer are:\n\n* Do these supplements improve sleep quality?\n* Do they reduce perceived stress levels?\n* Do they reduce anxiety symptoms?\n* What medical problems do participants have when taking these supplements?\n\nResearchers will compare three active treatment groups (lavender oil, PEA, Trpti which contains OEA) to a placebo (a look-alike capsule that contains no active ingredients) to see if these natural supplements work to improve sleep and reduce stress.\n\nParticipants will take 1 capsule (either active supplement or placebo) every day for 8 weeks and attend 2 clinic visits with a phone check in in between.",[103,104,105],"Sleep Disorder (Disorder)","Stress","Anxiety",[107],"Sleep complaints","RECRUITING","2026-04-22",{"date":111,"type":34},"2026-04-23",{"date":113,"type":34},"2026-04-07",{"date":115,"type":21},"2027-02",{"name":40,"class":41},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":42},"100626370","phase-4-a-study-to-see-if-an-energy-drink-with-caffeine-and-green-tea-increases-fat-burning-when-exercising-100626370","NCT07434752","A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising","Influence of Caffeine and Green Tea Extracts Consumption on Basal, Peri- and Post-exercise Fat Oxidation","Inclusion Criteria:\n\n* Passing the Exercise and Sport Science Australia adult pre-exercise screening system (APSS) stage 1 \\& 2 (see appendix 4).\n* Between the ages of 18 and 45,\n* Not sedentary, and not completing more than 150 minutes of low and\u002For moderate and\u002For or vigorous intensity endurance exercise a week,\n* Ability to commit to in principle fulfilment of all 3 trial visits,\n* No history of coagulopathy e.g., DVT, stroke,\n* No known heart disease,\n* No known pancreatic insufficiency,\n* No known inflammatory bowel disease, or prior bowel resection or bypass surgery (excluding gastric banding and sleeve),\n* BMI of 22.0 to 34.9 kg\u002Fm2,\n* No known allergies to caffeine or green tea extract,\n* No known type I or II diabetes,\n* No uncontrolled concurrent illness,\n* No known current pregnancy or breastfeeding women\n* No current regular consumption of supplements (\\>2 times a week) or foods and drinks containing caffeine and\u002For green tea extracts (\\>2 times per day, weekly).\n* Agree not to consume caffeine for 12-hours prior to the clinic visit.\n\nExclusion Criteria:\n\n* Triggering any of the exclusion screening criteria as outlined below, and in compliment with the Exercise and Sport Science Australia adult pre-exercise screening system (APSS).\n* Under the age of 18 or over the age of 45,\n* Sedentary, or completing over 150 minutes of low and\u002For moderate and\u002For or vigorous intensity endurance exercise a week,\n* Inability to commit to in principle fulfilment of all 3 trial visits,\n* History of coagulopathy e.g., DVT, stroke,\n* Known heart disease,\n* Known pancreatic insufficiency,\n* Known inflammatory bowel disease, or prior bowel resection or bypass surgery (excluding gastric banding and sleeve),\n* BMI \\\u003C 22.0 or \\> 34.9 kg\u002Fm2,\n* Known allergies to caffeine or green tea extract,\n* Known type I or II diabetes,\n* Uncontrolled concurrent illness,\n* Taking GLP-1 agonists, caffeine, or any other medication known to affect metabolism.\n* Known current pregnancy or breastfeeding women.\n* Currently regularly consuming supplements, foods or drinks containing a caffeine and green tea extract blend, or not willing to abstain for the study","45 Years",{"count":126,"type":21},40,[24],"The goal of this study is to evaluate the influence of consuming a drink containing a combination of caffeine and green tea extracts on fat oxidation responses at rest, during and after a period of endurance type exercise.",[130],"Exercise",[132],"metabolism","2026-04-13",{"date":135,"type":34},"2026-04-16",{"date":137,"type":34},"2026-03-26",{"date":38,"type":21},{"name":40,"class":41},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":42},"100571255","phase-2-long-term-pea-safety-study-100571255","NCT06717867","Long-Term PEA Safety Study","A Randomised, Double-blind Placebo-controlled Study in Healthy Adults to Assess Long Term Population Exposure to Palmitoylethanolamide (Levagen™) to Assess Clinical Safety.","Inclusion Criteria:\n\n* Adults (18 years and older)\n* Generally healthy\n* Able to provide informed consent\n* BMI 18.5 - 35.0 kg\u002Fm2\n* Agree to not participate in another clinical trial during enrolment period\n\nExclusion Criteria:\n\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years\n* Serious illness e.g., mood disorders (such as depression or bipolar disorder), anxiety, neurological disorders (such as MS), kidney disease, liver disease or heart conditions\n* Unstable illness (e.g., diabetes and thyroid gland dysfunction)\n* History of renal function impairment\n* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy \\[(excluding low dose aspirin (under 300 mg\u002Fday)\\]\n* Regular consumption (\\>4 times a week) of PEA over the past 2 weeks\n* Substance Abuse (illicit and\u002For prescription) Drug (prescription or illegal substances) abuse\n* Chronic past (within 12-months) and\u002For current alcohol use (\\>14 alcoholic drinks week)\n* Pregnant or lactating women\n* Allergic, sensitive, or intolerant to any of the ingredients in active or placebo formula\n* Has a clinically significant abnormal finding on the medical assessment, medical history, or clinical laboratory results at screening.\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.",{"count":148,"type":21},200,[56],"The goal of this clinical trial is to learn about the long term safety of PEA supplementation in healthy adults. This clinical trial will be in both males and females who are 18 years or older and are healthy volunteers.\n\nThe main aim of the study is to assess the safety of long-term use of PEA by assessing the difference between the two groups for serious adverse events, non-serious adverse events, vital signs and biochemistry following 12 months of PEA supplementation.\n\nParticipants will:\n\n* Have their suitability for the study checked against the full inclusion\u002Fexclusion criteria during the screening process.\n* Eligible participants will then complete a baseline visit where assessments will be performed and the participant will be randomly assigned to receive the study product or a placebo. Participants will then consume their assigned study product every day for 12 months. Participants will not know what product they have been assigned during the study.\n* Following the baseline visit, there will be 4 visits over 12 months. On months where participants do not have a visit there will be a check in phone call.\n* During visits there will be safety assessments performed, blood sampling and questionnaires.\n\nThe trial will include two participation modes:\n\n1. In-clinic participation (Brisbane): Participants will attend all visits in-person at the RDC Clinical facility.\n2. Remote participation for participants outside of Brisbane: A subgroup of up to 120 participants will participate remotely with virtual visits and at-home assessments. Participants will attend their local pathology centre for blood sampling.",[152,153],"Healthy","Safety",[155,156,157,158],"Palmitoylethanolamide","PEA","Levagen","PEA Safety study","2025-12-11",{"date":161,"type":34},"2025-12-18",{"date":163,"type":34},"2025-01-22",{"date":165,"type":21},"2027-06",{"name":40,"class":41},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":42},"100595136","phase-2-levagen-efficacy-study-on-diabetic-peripheral-neuropathy-100595136","NCT07028528","Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy","A Randomized Placebo Controlled Trial Assessing the Efficacy of Levagen+ for Treating Symptoms of Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults aged 18-75 years.\n* Using prescribed glucose-lowering medications, including oral medications (stable dose for 3 months or more) and\u002For insulin for diabetes (type 1 or 2).\n* Scoring12 or more on the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS).\n* Able to provide informed consent.\n* Agree not to change current diet and\u002For exercise frequency or intensity during entire enrolment period.\n* Agree to not participate in another clinical trial during the study period.\n* Able to attend an ACL collection centre.\n\nExclusion Criteria:\n\n* Peripheral neuropathy due to causes other than diabetes mellitus (e.g. nutritional deficiencies; hereditary sensory neuropathy; paraneoplastic diseases; advanced liver disease; kidney disease; hypothyroidism; prolonged phenytoin, warfarin or immunosuppressive drug use; active infection \\[HIV, Lyme disease, Epstein-Barr virus, Hepatitis C, Shingles, Leprosy\\]; autoimmune disease \\[Sjogren syndrome, Lupus, Rheumatoid arthritis, Guillain-Barre syndrome\\]; trauma \u002F injury; toxins \\[heavy metals, chemicals\\]; antibiotics; or inflammatory conditions \\[vasculitis\\]).\n* Serious illness e.g., paraneoplastic diseases, advanced liver disease, kidney disease, hypothyroidism, mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, or heart conditions, or peripheral vascular disease\n* Unstable illness e.g., diabetes and thyroid gland dysfunction, hypercholesterolemia\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.\n* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin\n* Herbal medicines for pain relief including, but not limited to, medicinal cannabis, willow bark (Salix alba), Boswellia (Boswellia serrata) or turmeric\u002Fcurcumin (Curcuma longa).\n* Active smokers, nicotine use or drug (prescription or illegal substances) abuse.\n* Chronic past and\u002For current alcohol use (\\>14 alcoholic drinks per week)\n* Females attempting to conceive, pregnant or lactating\n* Allergic, sensitive or intolerant to any of the ingredients in active or placebo formula.\n* Difficulty swallowing capsules.\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.","75 Years",{"count":176,"type":21},80,[56],"The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN.\n\nParticipants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks, from baseline to week 12 they will have remote visits every 3 weeks.",[180],"Diabetic Peripheral Neuropathy","2025-07-21",{"date":183,"type":34},"2025-07-23",{"date":185,"type":34},"2025-07-01",{"date":87,"type":21},{"name":40,"class":41},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":195,"minAge":196,"maxAge":174,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":42},"100457106","phase-3-effect-of-testofen-on-erectile-function-in-an-adult-male-population-100457106","NCT05232279","Effect of Testofen on Erectile Function in an Adult Male Population","Effect of Testofen on Erectile Function in an Adult Male Population - A Double Blind, Randomised Controlled Trial.","Inclusion Criteria:\n\n* Healthy male adults aged 40-75 years\n* Currently in a sexual relationship\n* Males with reduced erectile function (Score of \\\u003C25 on IIEF)\n* BMI ≤ 35\n* Able to provide informed consent\n* Agree not to change current diet and exercise program while enrolled in this trial\n* Agree not to undertake another clinical trial while enrolled in this trial\n\nExclusion Criteria:\n\n* History of prostate surgery and\u002For trauma\n* Receiving\u002Fprescribed treatment for erectile dysfunction, including oral medications, vacuum devices, constrictive devices, injections, or urethral suppositories\n* Receiving\u002Fprescribed treatment to increase\u002Fdecrease testosterone levels e.g. androgens\u002Fanti androgens\n* Receiving\u002Fprescribed treatment to increase\u002Fdecrease nitrate or nitric oxide levels\n* Unstable or serious illness (e.g. serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, diabetes, hormone production disorders)\\*\n* All current malignancies (excluding BCC) or chemotherapy and\u002For radiotherapy treatment for malignancy within the previous 2 years\n* Receiving\u002Fprescribed \\[e.g., Coumadin or Marevan (warfarin), heparin, dalteparin, enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use of vena cava filters)\n* Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances) abuse\n* Chronic past and\u002For current alcohol use (\\>14 alcoholic drinks week)\n* Allergic to any of the ingredients in the active or placebo formula\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion\n* Participants who have participated in any other related clinical study during the past 1 month\n\na Any participant reporting having been told by their doctor that they have an under or over production of hormones (e.g., testosterone).\n\n\\*An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and\u002For is burdensome in symptoms and\u002For treatments.","MALE","40 Years",{"count":198,"type":21},120,[200],"PHASE3","This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.",[203],"Erectile Dysfunction",{"date":205,"type":34},"2025-07-24",{"date":207,"type":34},"2022-04-19",{"date":209,"type":21},"2026-06",{"name":40,"class":41},""]